{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T14:24:59Z","timestamp":1720535099055},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[1994,1,1]],"date-time":"1994-01-01T00:00:00Z","timestamp":757382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":9502,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1994]]},"DOI":"10.1093\/annonc\/5.suppl_1.s97","type":"journal-article","created":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T21:54:43Z","timestamp":1353362083000},"page":"S97-S103","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S1","title":["Immunotoxins:Is there a clinical value?"],"prefix":"10.1016","volume":"5","author":[{"given":"C.","family":"Gottstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bohlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Engert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0060","series-title":"Molecular action of toxins and viruses","first-page":"51","article-title":"Toxic lectins and related proteins","author":"Olsnes","year":"1982"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0065","series-title":"Immunoconjugates: Antibody conjugates in radioimaging and therapy of cancer","first-page":"116","article-title":"Mediation of toxin entry into cells via naturally occurring ligand receptor sites","author":"Raso","year":"1987"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0014-4827(80)90270-0","article-title":"Entry of lethal doses of abrin, ricin, and modeccin into the cytosol of HeLa cells","volume":"126","author":"Eiklid","year":"1980","journal-title":"Exp Cell Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0075","series-title":"Monoclonal antibody therapy: Progress in allergy 45","first-page":"50","article-title":"Antibody toxin conjugates: A perspective","author":"Blakey","year":"1988"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0080","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1016\/S0021-9258(17)42707-4","article-title":"Kinetics of cytotoxicity induced by immunotoxins: Enhancement by lysosomotropic amines and carboxylic ionophores","volume":"259","author":"Casellas","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0085","first-page":"84","article-title":"Evaluation of ricin A-chain containing immunotoxins directed against CD30 as potential reagents for the treatment of Hodgkin\u2019s disease","volume":"50","author":"Engert","year":"1990","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0090","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ijc.2910420527","article-title":"Evaluation of four CD22 antibodies as ricin A-chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas","volume":"42","author":"Shen","year":"1988","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0095","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.4049\/jimmunol.141.12.4410","article-title":"Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells","volume":"141","author":"Press","year":"1988","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0100","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.3317828","article-title":"Redesigning nature\u2019s poisons to create anti-tumor reagents","volume":"238","author":"Vitetta","year":"1987","journal-title":"Science"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0105","series-title":"Monoclonal antibodies \u201884: Biological and clinical applications","first-page":"475","article-title":"Antibody carriers of cytotoxic agents in cancer therapy: A review","author":"Thorpe","year":"1985"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0110","first-page":"329","article-title":"Therapeutic strategies with monoclonal antibodies and immunoconjugates","volume":"65","author":"Byers","year":"1988","journal-title":"Immunology"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0115","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0003-2697(87)90073-X","article-title":"Purification of immunotoxins containing ricin A-chain and abrin A-chain using Blue Sepharose CL-6B","volume":"160","author":"Knowles","year":"1987","journal-title":"Ann Biochem"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0120","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0167-4889(88)90005-5","article-title":"Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo","volume":"968","author":"Blakey","year":"1988","journal-title":"Biochem Biophys Acta"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1432-1033.1985.tb08737.x","article-title":"Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution","volume":"147","author":"Thorpe","year":"1985","journal-title":"Eur J Biochem"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0130","first-page":"947","article-title":"Effect of chemical deglycosylation of ricin A-chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A-chain and anti-Thy 1.1 antibody","volume":"47","author":"Blakey","year":"1987","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0135","first-page":"2618","article-title":"Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: Effect of antibody valency and deglycosylation of the ricin A-chain on clearance and tumor localization","volume":"48","author":"Fulton","year":"1988","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0140","first-page":"2626","article-title":"In vivo therapy of BCL1 tumor: Effect of immunotoxin valency and deglycosylation of the ricin A-chain","volume":"48","author":"Fulton","year":"1988","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0145","first-page":"5924","article-title":"New coupling agents for the synthesis of immunotoxins containing a hindered disulphide bond with improved stability in vivo","volume":"47","author":"Thorpe","year":"1987","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0150","first-page":"6396","article-title":"Improved antitumour effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulphide linkages","volume":"48","author":"Thorpe","year":"1988","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0155","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1084\/jem.155.6.1797","article-title":"In vivo therapy of a murine B-cell tumor (BCL1) using antibody-ricin A-chain immunotoxins","volume":"155","author":"Krolick","year":"1982","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0160","first-page":"4420","article-title":"Guinea pig line 10 hepatocarcinoma model: Characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A-chain","volume":"43","author":"Bernhard","year":"1983","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0165","first-page":"2929","article-title":"Anti-tumor effects of ricin A-chain immunotoxins prepared from intact antibodies and Fab\u2032 fragments on solid human Hodgkin\u2019s disease tumors in mice","volume":"50","author":"Engert","year":"1990","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0170","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ijc.2910490324","article-title":"Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice","volume":"49","author":"Engert","year":"1991","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0175","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V83.2.466.466","article-title":"Successful treatment of disseminated human Hodgkin\u2019s disease in SCID mice with deglycosylated ricin A chain immunotoxins","volume":"83","author":"Winkler","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0180","first-page":"5876","article-title":"Antitumor activity of Fab\u2032 and IgG-anti-CD22 immunotoxins in disseminated human B-lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites","volume":"51","author":"Ghetie","year":"1991","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0185","first-page":"1314","article-title":"Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7","volume":"52","author":"Jansen","year":"1992","journal-title":"Cancer"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0190","first-page":"1101","article-title":"Comparison of two anti-Thy 1.1 abrin A-chain immunotoxins prepared with different cross-linking agents: Antitumor effects, in vivo fate, and tumor-cell mutants","volume":"79","author":"Thorpe","year":"1987","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0195","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1182\/blood.V80.9.2315.2315","article-title":"The antitumour activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin","volume":"80","author":"Ghetie","year":"1992","journal-title":"Blood"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0200","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4049\/jimmunol.100.2.376","article-title":"Relationship between molecular size and intra- and extravascular distribution of protein antigens","volume":"100","author":"Nakamura","year":"1968","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0205","first-page":"2610","article-title":"Evaluation of ricin A-chain immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy","volume":"48","author":"Ghetie","year":"1988","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0210","first-page":"1367","article-title":"Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates","volume":"79","author":"Smyth","year":"1987","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0215","first-page":"613","article-title":"Recombinant ricin A-chain conjugated to monoclonal antibodies: Improved tumor-cell inhibition in the presence of lysosomotropic compounds","volume":"49","author":"Ramakrisknan","year":"1989","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0220","first-page":"579","article-title":"Combined immuno-chemotherapy of human solid tumors in nude mice","volume":"47","author":"Weil-Hillman","year":"1987","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0225","first-page":"47","article-title":"Immunotoxins containing ricin or its A-chain","volume":"2","author":"Vitetta","year":"1991","journal-title":"Seminars in Cell Biology"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0230","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood.V75.7.1426.1426","article-title":"Use of an anti-pan T-lymphocyte ricin A-chain immunotoxin in steroid-resistant acute graft-versus-host disease","volume":"75","author":"Byers","year":"1990","journal-title":"Blood"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0235","series-title":"Immunotoxins","first-page":"493","article-title":"Clinical studies: Solid tumors","author":"Spitler","year":"1988"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0240","first-page":"6153","article-title":"Phase I study of monoclonal antibody-ricin A-chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer","volume":"49","author":"Byers","year":"1989","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0245","first-page":"4062","article-title":"Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A-chain immunoconjugate","volume":"49","author":"Weiner","year":"1989","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0250","first-page":"205a","article-title":"Immunotoxin therapy of relapsed B-lineage ALL: A clinical phase I dose escalation study of B43 (anti-CD19) pokeweed antiviral protein (PAP) immunotoxin","volume":"80","author":"Uckun","year":"1992","journal-title":"Blood"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0255","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/0140-6736(92)91135-U","article-title":"Response of refractory Hodgkin\u2019s disease to monoclonal anti-CD30 immunotoxin","volume":"339","author":"Falini","year":"1992","journal-title":"Lancet"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0260","first-page":"4052","article-title":"Phase I immunotoxin trial in patients with B-cell lymphoma","volume":"51","author":"Vitetta","year":"1991","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0265","unstructured":"Amlot PL, Stone MJ, Fay J et al. A phase I study of an anti-CD22-deglycocylated ricin A-chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood (in press)."},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0270","first-page":"44a","article-title":"Phase I study of murine monoclonal antibody HD37-deglycosylated ricin A-chain in chemotherapy resistant B-cell lymphoma","volume":"80","author":"Conry","year":"1992","journal-title":"Blood"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0275","series-title":"Proc Am Soc Clin Oncol","first-page":"975a","article-title":"Clinical application of a ricin A-chain immunotoxin in patients with resistant Hodgkin\u2019s disease","author":"Engert","year":"1993"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0280","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/cdd.1987.4.245","article-title":"Humoral immune response to a ricin A-chain immunotoxin in patients with metastatic melanoma","volume":"4","author":"Hertler","year":"1987","journal-title":"Cancer Drug Deliv"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0285","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.1073\/pnas.80.20.6332","article-title":"Synergy of ricin A-chain-containing immunotoxins in in vitro killing of neoplastic human B cells","volume":"80","author":"Vitetta","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0290","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1084\/jem.160.1.341","article-title":"Cytotoxicity of a cell-reactive immunotoxin containing ricin A chain is potentiated by an immunotoxin containing ricin B chain","volume":"160","author":"Vitetta","year":"1984","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0295","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF01789046","article-title":"Blocked and nonblocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A-chain immunotoxin potentiated with ricin B chain or with a ricin B-chain immunotoxin","volume":"32","author":"Wawrynczak","year":"1991","journal-title":"Cancer Immunol Immunother"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0300","first-page":"4469","article-title":"Novel synthesis and in vitro characterization of disulphide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity","volume":"48","author":"Pietersz","year":"1988","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0305","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1021\/bi00227a011","article-title":"The galactose sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides","volume":"30","author":"Lambert","year":"1991","journal-title":"Biochem"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0310","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF01741150","article-title":"Blocked ricinconjugated T-cell immunotoxins: Effect of anti-CD6-blocked ricin on normal T-cell function","volume":"35","author":"Rasmussen","year":"1992","journal-title":"Cancer Immunol Immunother"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0315","first-page":"6236","article-title":"An immunotoxin prepared with blocked ricin: A natural plant toxin adapted for therapeutic use","volume":"51","author":"Lambert","year":"1991","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0320","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1182\/blood.V77.11.2404.2404","article-title":"Anti-My9-blocked ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells","volume":"77","author":"Roy","year":"1991","journal-title":"Blood"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0325","first-page":"1360","article-title":"Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models","volume":"53","author":"Shah","year":"1993","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0330","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00199994","article-title":"Blocked and not blocked whole-ricin-antibody immunotoxins: Intraperitoneal therapy of human tumour xenografted in nude mice","volume":"29","author":"Brusa","year":"1989","journal-title":"Cancer Immunol Immunother"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0335","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/BF01789015","article-title":"Antitumor activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice","volume":"35","author":"Brusa","year":"1992","journal-title":"Cancer Immunol Immunother"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0340","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood.V79.3.576.576","article-title":"Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion","volume":"79","author":"Grossbard","year":"1991","journal-title":"Blood"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0345","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.1993.11.4.726","article-title":"Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms","volume":"11","author":"Grossbard","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0350","series-title":"Proc Am Soc Clin Oncol","first-page":"1265a","article-title":"Adjuvant therapy with anti-B4-blocked ricin after ABMT for B-NHL","author":"Grossbard","year":"1993"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0355","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0092-8674(87)90363-1","article-title":"Functional domains of PE identified by deletion analysis of the gene expressed in E. coli","volume":"48","author":"Hwang","year":"1987","journal-title":"Cell"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0360","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1073\/pnas.87.1.308","article-title":"PE contains a specific sequence at the caboxyl terminus that is required for cytotoxicity","volume":"87","author":"Chaudhary","year":"1990","journal-title":"Proc Natl Acad Sci"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0365","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1126\/science.1683495","article-title":"Recombinant toxins for cancer treatment","volume":"254","author":"Pastan","year":"1991","journal-title":"Science"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0370","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1073\/pnas.84.13.4538","article-title":"Activity of a recombinant fusion protein between TGFa and Pseudomonas exotoxin","volume":"84","author":"Chaudhary","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0375","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/protein\/1.6.493","article-title":"Diphtheria toxin binding domain substitution with IL-2: Genetic construction and properties of a diphtheria toxin-related IL-2 fusion protein","volume":"1","author":"Williams","year":"1987","journal-title":"Protein Ing"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0380","first-page":"3189","article-title":"Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE in monkeys","volume":"52","author":"Pai","year":"1992","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0385","doi-asserted-by":"crossref","first-page":"8616","DOI":"10.1073\/pnas.88.19.8616","article-title":"B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regressions of a human carcinoma in mice","volume":"88","author":"Brinkmann","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0390","first-page":"360a","article-title":"Phase I study of genetically engineered DAB486IL2 in IL2-expressing malignancies","volume":"76","author":"LeMaistre","year":"1990","journal-title":"Blood"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0395","first-page":"175a","article-title":"Complete response of a Hodgkin\u2019s lymphoma patient in a phase I trial of DAB486IL2, an IL2-diphtheria fusion toxin","volume":"78","author":"Schwartz","year":"1991","journal-title":"Blood"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0400","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1073\/pnas.81.21.6851","article-title":"Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains","volume":"81","author":"Morrison","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0405","series-title":"Proc Am Soc Clin Oncol","first-page":"945a","article-title":"Supression of human antimouse antibody response (HAMA) by deoxyspergualin (DSG): A phase I study","author":"Dhingra","year":"1993"},{"key":"10.1093\/annonc\/5.suppl_1.S97_bb0410","first-page":"5954","article-title":"A murine model for antibody directed targeting of vascular endothelial cells in solid tumors","volume":"52","author":"Burrows","year":"1992","journal-title":"Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419633740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419633740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/5\/suppl_1\/S97\/6679792\/5-suppl_1-S97.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T14:39:37Z","timestamp":1714574377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419633740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994]]},"references-count":71,"alternative-id":["S0923753419633740"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/5.suppl_1.s97","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1994]]}}}